Manufacturing and Supply Deals in Pharmaceuticals and Biotechnology 2021-2026
Manufacturing and Supply Deals in Pharmaceuticals and Biotechnology | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Comprehensive deal directory 2021 to 2026
Benchmark Manufacturing and Supply Partnerships Across the Global Biopharma Industry
The Manufacturing and Supply Deals in Pharmaceuticals and Biotechnology report provides a comprehensive analysis of manufacturing and supply partnerships across the global life sciences industry. Designed for business development, licensing, and operations professionals, the report delivers detailed insight into how companies structure manufacturing agreements, negotiate financial terms, and establish supply relationships to support drug development and commercialization.
Fully revised and updated, the report provides a comprehensive listing of manufacturing and supply deals announced in recent years, drawn from the Current Agreements deals and alliances database. Each deal record includes financial information where available and links to detailed online deal records and contract documents filed with regulators when publicly disclosed.
By combining detailed deal data, financial benchmarking, and access to real contract documents, the report provides valuable intelligence for evaluating potential partners, structuring supply agreements, and negotiating more effective manufacturing partnerships.
Key Benefits
✔ Save Significant Research Time
Access a consolidated database of manufacturing and supply agreements instead of searching multiple databases, press releases, and regulatory filings.
✔ Benchmark Manufacturing and Supply Deal Structures
Understand how pharmaceutical and biotechnology companies structure manufacturing and supply partnerships, including responsibilities, operational roles, and long-term supply arrangements.
✔ Analyze Financial Terms with Confidence
Review disclosed financial terms and transaction values to benchmark the commercial structure of comparable manufacturing agreements.
✔ Access Real Contract Documents
Where available, explore SEC-filed manufacturing and supply agreements, providing deeper insight into the detailed contractual provisions behind real-world partnerships.
✔ Identify Leading Manufacturing and Supply Dealmakers
Discover which companies are most active in manufacturing partnerships and analyze their outsourcing and supply chain strategies.
✔ Track Industry Trends
Analyze manufacturing and supply dealmaking trends across companies, therapeutic areas, and technology types to understand how outsourcing and production strategies are evolving.
What’s Included in the Report
-
Analysis of manufacturing and supply dealmaking trends
-
Overview of manufacturing and supply agreement structures
-
Review of the leading manufacturing and supply deals by value
-
Profiles of the most active manufacturing and supply dealmakers
-
Detailed analysis of deals organized by company, therapeutic area, technology type, and industry sector
-
A comprehensive deal directory covering manufacturing and supply agreements recorded in the Current Agreements database
-
Links to online deal records and contract documents where available
Due Diligence Insights from Real Agreements
By reviewing actual manufacturing and supply contracts, the report enables users to evaluate key partnership provisions such as:
-
Manufacturing responsibilities and production commitments
-
Supply terms and commercial obligations
-
Financial payment structures and pricing mechanisms
-
Exclusivity provisions and territorial supply rights
-
Quality control and regulatory compliance responsibilities
-
Contract duration and termination provisions
Contract documents provide critical insight into the detailed terms negotiated between partners—information that is often not available in press releases or traditional deal databases.
Why This Report Matters
Manufacturing and supply partnerships are essential to the successful development and commercialization of pharmaceutical and biotechnology products. Companies increasingly rely on external partners to scale production, expand capacity, and access specialized manufacturing technologies.
By providing comprehensive deal data, financial benchmarking, and access to real contract documents, this report delivers the intelligence needed to structure stronger manufacturing partnerships, evaluate outsourcing strategies, and negotiate more effective supply agreements.
Key Benefits
✔ Save Significant Research Time
Access a consolidated database of manufacturing and supply agreements instead of searching multiple databases, press releases, and regulatory filings.
✔ Benchmark Manufacturing and Supply Deal Structures
Understand how pharmaceutical and biotechnology companies structure manufacturing and supply partnerships, including responsibilities, operational roles, and long-term supply arrangements.
✔ Analyze Financial Terms with Confidence
Review disclosed financial terms and transaction values to benchmark the commercial structure of comparable manufacturing agreements.
✔ Access Real Contract Documents
Where available, explore SEC-filed manufacturing and supply agreements, providing deeper insight into the detailed contractual provisions behind real-world partnerships.
✔ Identify Leading Manufacturing and Supply Dealmakers
Discover which companies are most active in manufacturing partnerships and analyze their outsourcing and supply chain strategies.
✔ Track Industry Trends
Analyze manufacturing and supply dealmaking trends across companies, therapeutic areas, and technology types to understand how outsourcing and production strategies are evolving.
Executive Summary
Chapter 1 – Introduction
Chapter 2 – Trends in manufacturing and supply dealmaking
2.1. Introduction
2.2. Definition of manufacturing and supply deal
2.3. Trends in manufacturing and supply deals since 2021
2.3.1. Manufacturing and supply dealmaking by year
2.3.2. manufacturing and supply dealmaking by phase of development
2.3.3. Manufacturing and supply dealmaking by industry sector
2.3.4. Manufacturing and supply dealmaking by therapy area
2.3.5. Manufacturing and supply dealmaking by technology type
2.3.6. Manufacturing and supply dealmaking by most active company
2.4. Reasons for entering into manufacturing and supply partnering deals
2.5. The future of manufacturing and supply deals
Chapter 3 – Overview of manufacturing and supply deal structure
3.1. Introduction
3.2. manufacturing and supply agreement structure
Chapter 4 – Leading manufacturing and supply deals
4.1. Introduction
4.2. Top manufacturing and supply deals by value
Chapter 5 – Top 25 most active manufacturing and supply dealmakers
5.1. Introduction
5.2. Top 25 most active manufacturing and supply dealmakers
Chapter 6 – manufacturing and supply deals including contracts directory
6.1. Introduction
6.2. manufacturing and supply deals with contracts
Deal directory
Deal directory – manufacturing and supply dealmaking by companies A-Z
Deal directory – manufacturing and supply dealmaking by therapy area
Deal directory – manufacturing and supply dealmaking by technology type
About Biopharma Research Ltd
Current Partnering
Current Agreements
Recent report titles from Current Partnering
TABLE OF FIGURES
Figure 1: Definition of manufacturing and supply
Figure 2: Trends in manufacturing and supply deal announcements
Figure 3: Manufacturing and supply deals signed at each phase of development
Figure 4: Manufacturing and supply deals by industry sector
Figure 5: Manufacturing and supply deals by therapy area
Figure 6: Manufacturing and supply deals by technology type
Figure 7: Top 25 most active manufacturing and supply dealmakers
Figure 8: Top manufacturing and supply deals by value
Figure 9: Most active manufacturing and supply dealmakers
Pricing options
- $3,995: single-user (encrypted file - one user/device)
- $5,995: multi-user (encrypted file - up to 5 users/devices)
- $7,995: company (unencrypted file)
Single and Multi-user license files are encrypted PDF documents. Details of how to access using Javelin3 PDF Reader will be provided at report delivery.
Company license files are not encrypted and can be accessed using a PDF Reader.
A full explanation of license type definitions can be found here.
Our guarantee
Delivery Deadline
We guarantee that the report will be sent within the specified delivery times. In the unlikely case of a delay we may offer a partial refund as compensation. (Terms may apply)
Latest report
If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.
Serious Security
We take your data and security seriously. See our privacy policy for details of how we manage your data.
Sales Support
If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.
- Total Trust
Current Partnering is part of Biopharma Research Ltd based in County Durham, United Kingdom. We have been trading successfully online since 2012 and work with some of the most famous brands in the business. We carefully select our partners to ensure that the publications meet expectations of demanding customers.
About Current Partnering
A definitive, evidence-based approach to dealmaking intelligence
Current Partnering is the industry-leading provider of pharmaceutical and biotech dealmaking intelligence, delivering a clear, structured, and evidence-based view of how partnerships are designed, negotiated, and executed in practice.
Our reports combine comprehensive deal coverage, structured data analysis, and contract-level insight, enabling a deeper understanding of how financial terms, rights, and responsibilities are defined across real-world transactions.
All reports are updated every six months, ensuring users have access to the latest deal activity, trends, and market developments.
Our methodology
Built on a continuously updated proprietary database
All analysis is underpinned by Current Agreements, our proprietary deals and alliances database which is updated daily by our analysts as new transactions are announced globally.
Deal records are continuously reviewed and enriched as additional information becomes available, ensuring accuracy, completeness, and relevance.
Comprehensive and verifiable data sourcing
Deal data is sourced from publicly available industry disclosures, including:
- Company press releases and announcements
- SEC filings and equivalent regulatory disclosures
- Company and investor presentations
- Conference materials and company websites
All sources are captured and referenced, enabling full transparency and user verification.
Broad coverage across deal types and structures
Current Partnering provides comprehensive coverage across a wide range of deal types, including but not limited to:
- Licensing and co-development
- Research and collaborative R&D
- Manufacturing, supply, and distribution
- Commercialisation and co-promotion
- Equity investments, joint ventures, and asset transactions
- Options, royalties, and financing agreements
This breadth ensures a complete view of how partnerships are structured across the life sciences sector.
Structured, standardised analysis
Every deal is analysed using a consistent framework, capturing (where disclosed):
- Financial terms — including upfront payments, milestones, and royalties
- Rights allocation — development, manufacturing, and commercialization responsibilities
- Deal structure — exclusivity, territorial scope, and agreement type
- Contractual provisions — clauses defining risk, control, and value-sharing
Each deal record is fully categorised, including data fields such as:
- Therapy area and technology type
- Stage of development
- Asset type and deal components
- Geographic scope and exclusivity
- Source documentation, including press releases and SEC filings
Financial normalisation for comparability
All financial values are standardised to USD using the exchange rate at the time of deal announcement, enabling consistent comparison of deal terms across geographies.
Contract-level insight
Where available, reports include direct access to underlying agreement documents, providing visibility into how deals are constructed in practice.
This enables users to understand:
- How financial mechanisms are defined and triggered
- How responsibilities are operationalised between parties
- How flexibility, risk, and control are allocated within agreements
Designed for real-world application
Current Partnering reports are built to support business-critical decision-making across the life sciences ecosystem, including:
- Pharmaceutical and biotech companies — benchmarking deals, structuring transactions, and supporting licensing strategy
- Investment firms and venture capital — assessing deal benchmarks, valuation expectations, and partner behaviour
- Advisory, legal, and consulting firms — supporting client engagements with real-world precedent and contract-level insight
Common use cases include:
- Benchmarking comparable transactions
- Supporting valuation and deal structuring
- Preparing for negotiations
- Evaluating potential partners
- Informing internal strategy with real-world evidence
A trusted industry reference
With a long track record in the sector, Current Partnering is relied upon by leading pharmaceutical companies, emerging biotechs, investors, and advisory firms as a trusted source of dealmaking intelligence.
By combining proprietary data, rigorous methodology, and contract-level insight, our reports provide a reliable and authoritative foundation for understanding how deals are structured, negotiated, and valued.
